ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of March 27, 2023, ABOS stock price declined to $3.82 with 32,476 million shares trading.

ABOS has a beta of 0.28, meaning it tends to be less sensitive to market movements. ABOS has a correlation of 0.00 to the broad based SPY ETF.

ABOS has a market cap of $156.33 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IBB, IWC, DFAU.

ABOS has underperformed the market in the last year with a price return of -32.6% while the SPY ETF lost -10.6%. ABOS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.7% and -16.2%, respectively, while the SPY returned +3.9% and +3.1%, respectively.

ABOS support price is $3.67 and resistance is $4.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS stock will trade within this expected range on the day.